Navigation Links
Nile Therapeutics, Inc. Completes $3.4 Million Private Placement
Date:7/16/2009

SAN FRANCISCO, July 16 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX), a company focused on the development of novel therapeutics for heart failure patients, today announced that it has completed a private placement of shares of its common stock and warrants to purchase additional common stock for aggregate gross proceeds of approximately $3.4 million. Riverbank Capital Inc., a FINRA member broker dealer acted as the exclusive placement agent for the transaction.

"We are extremely pleased to have the completed this financing," said Joshua Kazam, Chief Executive Officer, "which we believe will provide us with sufficient capital to complete our Phase 2 clinical study of CD-NP in acute heart failure patients with mild to moderate renal insufficiency."

The securities sold in the private placement have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration under such act and applicable state securities laws or an applicable exemption from those registration requirements. Nile has agreed to file a registration statement covering the resale of the shares issued in the private placement, including the shares issuable upon exercise of the warrants. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

About Nile Therapeutics

Nile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas o
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oxygen Biotherapeutics, Inc. Announces Closing of Private Placement Financing Agreement
2. Nile Therapeutics, Inc. To Raise $3.4 Million in Private Placement
3. Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions
4. Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions
5. Prospect Therapeutics, Inc.s GCS-100 Inhibited Blood Vessel Formation in a Variety of Cancer Models
6. Cell Therapeutics, Inc. (CTI) to Present at 2009 BIO International Convention
7. Prospect Therapeutics, Inc. Assigns All Its Assets to Joseph F. Finn, Jr., C.P.A. for the Benefit of Its Creditors
8. Cell Therapeutics, Inc. (CTI) to Report 2009 First Quarter Financial Results on May 7
9. Oxygen Biotherapeutics, Inc. Signs Supply Agreement for Clinical-Grade Oxycyte for Clinical Trials and Future Needs
10. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $15 Million of Preferred Stock
11. Oxygen Biotherapeutics, Inc. CEO Posts New Blog Entry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... 2015 W. R. Grace & ... in Worms, Germany has received good manufacturing practice ... the International Pharmaceutical Excipient Council (IPEC) Foundation. ... its SYLOID® FP brand of pharmaceutical grade excipient ... the Curtis Bay, Maryland (USA) and Sorocaba, Brazil ...
(Date:5/21/2015)... As part of its philanthropic partnership with Banner ... funded a $3.25 million project to relocate and equip ... up-to-date features and technology. , The new pharmacy is ... members will begin moving from the current location to ... , The current pharmacy has been using a ...
(Date:5/21/2015)... (PRWEB) May 21, 2015 Veolia’s ... an exclusive North American distribution agreement with VWR ... system. , With more than 160 years of ... and services for laboratory and production facilities, has ... excellence and differentiated services to enable science. ...
(Date:5/20/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/x4b7kw/top_technologies ... Technologies in HW_Technical Insights" report to their offering. ... technology trends in the Health and Wellness sector and ... have an impact in the year 2015. The research ... 10 health and wellness technologies that are anticipated to ...
Breaking Biology Technology:Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2Sun Health Foundation Provides $3.25M to Expand, Relocate Banner Del E. Webb Medical Center Pharmacy 2Sun Health Foundation Provides $3.25M to Expand, Relocate Banner Del E. Webb Medical Center Pharmacy 3Veolia’s TECTA™ B16 Instrument for E. Coli Detection is Offered Exclusively Through VWR 2Top Technologies in the Health and Wellness Industry 2015 2
... VIEW, Calif., Jan. 26 Based on its ... & Sullivan recognizes ESBATech with the 2009 North ... Year Award for its work in developing antibody ... antibody fragment therapeutics addresses and overcomes many of ...
... (OTC Bulletin Board: PDAE) today announced that its Hereford ... under Chapter 11 of the United States Bankruptcy Code ... District of Texas. The company intends to sell its ... Section 363 sale process approved by the bankruptcy court. ...
... JOLLA, Calif., Jan. 23 Cordex Pharma, Inc., formerly known ... that it will host a scientific briefing on Thursday, January ... The keynote speaker will be Jonathan S. Stamler, MD, the ... a Professor of Medicine and of Biochemistry at Duke ...
Cached Biology Technology:Frost & Sullivan Recognizes ESBATech's Innovation in Developing Antibody Fragments for Biologic Therapeutics 2Frost & Sullivan Recognizes ESBATech's Innovation in Developing Antibody Fragments for Biologic Therapeutics 3Frost & Sullivan Recognizes ESBATech's Innovation in Developing Antibody Fragments for Biologic Therapeutics 4Panda Ethanol's Hereford, Texas Subsidiary Files Voluntary Chapter 11 2Panda Ethanol's Hereford, Texas Subsidiary Files Voluntary Chapter 11 3Cordex Pharma Presents 'New Frontiers in Cardiovascular Medicines' on January 29 2Cordex Pharma Presents 'New Frontiers in Cardiovascular Medicines' on January 29 3Cordex Pharma Presents 'New Frontiers in Cardiovascular Medicines' on January 29 4Cordex Pharma Presents 'New Frontiers in Cardiovascular Medicines' on January 29 5
(Date:5/20/2015)... DUBLIN , May 20, 2015 ... Markets ( http://www.researchandmarkets.com/research/h8t4x6/5year ) has announced the ... of the Global Iris Recognition Market" ... http://photos.prnewswire.com/prnh/20130307/600769) , ,This research service analyses ... across the government and commercial sectors, ...
(Date:5/18/2015)... Fingerprint Cards (FPC) has received an ... and FPC1035 from one if its module partners. Deliveries are ... 2015 and the sensors will be used by smartphone manufacturers ... 2015 hereby amount to 740 MSEK to date. In addition ... and a number of smaller orders not separately communicated amounting ...
(Date:5/11/2015)... N.Y. , May 11, 2015 Curemark ... announced the start of a new Phase III double ... of its novel formulation, CM-AT, on all children ages ... of its FDA Phase III double blinded clinical trial ... had low levels of the digestive enzyme chymotrypsin. This ...
Breaking Biology News(10 mins):Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2
... PITTSBURGHCarnegie Mellon University researchers have found that within ... neurons that behave much like people in social networks. ... of highly active members who give and receive more ... Barth, associate professor of biological sciences at Carnegie Mellon ...
... 10, 2011 Cleveland Researchers have discovered a ... undergo testing for genetic mutations of the tumor suppressor ... including several types of cancers. The research has created ... Led by Charis Eng, M.D., Ph.D., Chair of ...
... (January 9, 2011) - While age-related vision loss of ... million patients today to 55 million by the year 2050, ... vision even restored using molecular medicine. ... at the 10th annual meeting and International Conference on Recent ...
Cached Biology News:Carnegie Mellon researchers identify 'Facebook neurons' 2Carnegie Mellon researchers identify 'Facebook neurons' 3Researchers create 'scoring system' for PTEN mutation testing 2Molecular medicine could avert predicted catastrophic vision loss in the aged 2Molecular medicine could avert predicted catastrophic vision loss in the aged 3
Viral CMV UL146/vCXC1 Biotinylated Affinity Purified PAb...
Request Info...
D-biotin *50 mM aqueous solution* Secondary Detection Biotin–Avidin Detection Reagents Other...
... strains are high-performance BL21 ... protein yield in T7 ... 1). Because the T7 ... more rapidly than E. ...
Biology Products: